Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 5,175 | 19,223 | 14,745 | 4,546 | 26,082 |
| Cost of Goods | 14,687 | 20,161 | 21,829 | 12,794 | 12,079 |
| Gross Profit | -9,512 | -938 | -7,084 | -8,248 | 14,003 |
| Operating Expenses | 163,377 | 175,450 | 185,113 | 176,313 | 112,436 |
| Operating Income | -172,202 | -176,227 | -191,368 | -183,767 | -98,354 |
| Other Income | 9,952 | 4,330 | -11,277 | 4,869 | 2,679 |
| Pre-tax Income | -162,250 | -171,897 | -202,645 | -178,898 | -95,675 |
| Income Tax | 3 | 0 | -158 | 8 | 167 |
| Net Income Continuous | -162,253 | -171,897 | -202,487 | -178,906 | -95,842 |
| Net Income | $-162,253 | $-171,897 | $-202,487 | $-178,906 | $-95,842 |
| EPS Basic Total Ops | -0.36 | -0.41 | -0.50 | -0.56 | -0.34 |
| EPS Basic Continuous Ops | -0.36 | -0.41 | -0.50 | -0.56 | -0.34 |
| EPS Diluted Total Ops | -0.36 | -0.41 | -0.50 | -0.56 | -0.34 |
| EPS Diluted Continuous Ops | -0.36 | -0.41 | -0.50 | -0.56 | -0.34 |
| EPS Diluted Before Non-Recurring Items | -0.36 | -0.41 | -0.50 | -0.53 | -0.34 |
| EBITDA(a) | $-151,159 | $-152,378 | $-172,037 | $-170,816 | $-91,156 |